PDCD1 and soft tissue sarcoma: In the phase 2 clinical trial of anit-PD-1 inhibitor pembrolizumab in advanced soft tissue sarcomas (SARC028) [27], it was noted that higher baseline density of TILs in the tumor immune microenvironment was correlated with objective response rate [28], and patients with a B cell rich immune signature demonstrated high response rates [29].